Summary of responses based on the AUTO3 dose received
| . | 50 × 106 AUTO3 No Pembro. (N = 4) . | 50 × 106 AUTO3 D14 Pembro. (N = 3) . | 150 × 106-450 × 106 AUTO3 D14 Pembro. (N = 8) . | 150 × 106-450 × 106 AUTO3 D-1 Pembro. inpatient (N = 17) . | 150 × 106-450 × 106 AUTO3 D-1 Pembro. OPD (N = 20) . | Total (N = 52) . |
|---|---|---|---|---|---|---|
| N evaluable∗ | 4 | 2 | 8 | 16 | 17 | 47 |
| ORR (CR + PR) | 2 (50%) | 2 (100%) | 5 (62.5%) | 10 (62.5%) | 12 (70.6%) | 31 (66.0%) |
| CR | 1 (25%) | 1 (50%) | 4 (50%) | 9 (56.3%) | 8 (47.1%) | 23 (48.9%) |
| PR | 1 (25%) | 1 (50%) | 1 (12.5%) | 1 (6.3%) | 4 (23.5%) | 8 (17%) |
| . | 50 × 106 AUTO3 No Pembro. (N = 4) . | 50 × 106 AUTO3 D14 Pembro. (N = 3) . | 150 × 106-450 × 106 AUTO3 D14 Pembro. (N = 8) . | 150 × 106-450 × 106 AUTO3 D-1 Pembro. inpatient (N = 17) . | 150 × 106-450 × 106 AUTO3 D-1 Pembro. OPD (N = 20) . | Total (N = 52) . |
|---|---|---|---|---|---|---|
| N evaluable∗ | 4 | 2 | 8 | 16 | 17 | 47 |
| ORR (CR + PR) | 2 (50%) | 2 (100%) | 5 (62.5%) | 10 (62.5%) | 12 (70.6%) | 31 (66.0%) |
| CR | 1 (25%) | 1 (50%) | 4 (50%) | 9 (56.3%) | 8 (47.1%) | 23 (48.9%) |
| PR | 1 (25%) | 1 (50%) | 1 (12.5%) | 1 (6.3%) | 4 (23.5%) | 8 (17%) |
D, day; PR, partial response rate; Pembro, pembrolizumab.
PET-positive disease before LD.